{"entity":{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","aka":[],"tldr":"A Texas biotech developing elraglusib, a GSK-3 beta inhibitor that improved survival in a randomised phase 2 in metastatic pancreatic cancer.","summary":"Actuate Therapeutics listed on Nasdaq in 2024 to fund elraglusib. Its lead programme is first-line metastatic pancreatic cancer with gemcitabine and nab-paclitaxel, where the Actuate 1801 Part 3B randomised phase 2 reported longer survival; the company is planning a confirmatory phase 3 and also studies the drug in Ewing sarcoma and other tumours.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.actuatetherapeutics.com"}],"tags":[],"related":[],"cancers":["pancreatic","ewing-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["elraglusib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fort Worth, Texas, United States","country":"US","companyType":"biotech","website":"https://www.actuatetherapeutics.com","founded":2015,"stage":"public","investors":[],"funding":[]},"route":"/companies/actuate-therapeutics/","neighbours":{"cancer":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/"}]}}